Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species

Alycen Paige Lundberg, Joshua M. Francis, Malgorzata Pajak, Elizabeth I. Parkinson, Kathryn L. Wycislo, Thomas J. Rosol, Megan E. Brown, Cheryl A. London, Levent Dirikolu, Paul Hergenrother, Timothy M Fan

Research output: Contribution to journalArticle

Abstract

Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1), an enzyme overexpressed in many solid tumors. Following activation by NQO1, IB-DNQ participates in a catalytic futile reduction/reoxidation cycle with consequent toxic reactive oxygen species generation within the tumor microenvironment. To elucidate the potential of IB-DNQ to serve as a novel anticancer agent, in vitro studies coupled with in vivo pharmacokinetic and toxicologic investigations in the domestic felid species were conducted to investigate the tractability of IB-DNQ as a translationally applicable anticancer agent. First, using feline oral squamous cell carcinoma (OSCC) as a comparative cancer model, expressions of NQO1 were characterized in not only human, but also feline OSCC tissue microarrays. Second, IB-DNQ mediated cytotoxicity in three immortalized feline OSCC cell lines were studied under dose-dependent and sequential exposure conditions. Third, the feasibility of administering IB-DNQ at doses predicted to achieve cytotoxic plasma concentrations and biologically relevant durations of exposure were investigated through pharmacokinetic and tolerability studies in healthy research felines. Intravenous administration of IB-DNQ at 1.0–2.0 mg/kg achieved peak plasma concentrations and durations of exposure reaching or exceeding predicted in vitro cytotoxic concentrations. Clinical adverse side effects including ptyalism and tachypnea exhibited during and post-IV infusion of IB-DNQ were transient and tolerable. Additionally, IB-DNQ administration did not produce acute or delayed-onset unacceptable hematologic, non-hematologic, or off-target oxidative toxicities. Collectively, the findings reported here within provide important safety and pharmacokinetic data to support the continued development of IB-DNQ as a novel anticancer strategy for NQO1 expressing cancers.

Original languageEnglish (US)
Pages (from-to)134-144
Number of pages11
JournalInvestigational New Drugs
Volume35
Issue number2
DOIs
StatePublished - Apr 1 2017

Fingerprint

Pharmacokinetics
Felidae
Neoplasms
Squamous Cell Carcinoma
Antineoplastic Agents
deoxynyboquinone
Tachypnea
Tumor Microenvironment
Poisons
Intravenous Administration
NAD
Reactive Oxygen Species
Oxidoreductases
Safety
Cell Line
Enzymes
Research

Keywords

  • Comparative oncology
  • Deoxynyboquinone
  • Feline oral squamous cell carcinoma
  • NQO1
  • Novel anti-cancer agent
  • β-lapachone

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. / Lundberg, Alycen Paige; Francis, Joshua M.; Pajak, Malgorzata; Parkinson, Elizabeth I.; Wycislo, Kathryn L.; Rosol, Thomas J.; Brown, Megan E.; London, Cheryl A.; Dirikolu, Levent; Hergenrother, Paul; Fan, Timothy M.

In: Investigational New Drugs, Vol. 35, No. 2, 01.04.2017, p. 134-144.

Research output: Contribution to journalArticle

Lundberg, Alycen Paige ; Francis, Joshua M. ; Pajak, Malgorzata ; Parkinson, Elizabeth I. ; Wycislo, Kathryn L. ; Rosol, Thomas J. ; Brown, Megan E. ; London, Cheryl A. ; Dirikolu, Levent ; Hergenrother, Paul ; Fan, Timothy M. / Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species. In: Investigational New Drugs. 2017 ; Vol. 35, No. 2. pp. 134-144.
@article{f7110821bae746fc8a8e2cda6b56b5d3,
title = "Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species",
abstract = "Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1), an enzyme overexpressed in many solid tumors. Following activation by NQO1, IB-DNQ participates in a catalytic futile reduction/reoxidation cycle with consequent toxic reactive oxygen species generation within the tumor microenvironment. To elucidate the potential of IB-DNQ to serve as a novel anticancer agent, in vitro studies coupled with in vivo pharmacokinetic and toxicologic investigations in the domestic felid species were conducted to investigate the tractability of IB-DNQ as a translationally applicable anticancer agent. First, using feline oral squamous cell carcinoma (OSCC) as a comparative cancer model, expressions of NQO1 were characterized in not only human, but also feline OSCC tissue microarrays. Second, IB-DNQ mediated cytotoxicity in three immortalized feline OSCC cell lines were studied under dose-dependent and sequential exposure conditions. Third, the feasibility of administering IB-DNQ at doses predicted to achieve cytotoxic plasma concentrations and biologically relevant durations of exposure were investigated through pharmacokinetic and tolerability studies in healthy research felines. Intravenous administration of IB-DNQ at 1.0–2.0 mg/kg achieved peak plasma concentrations and durations of exposure reaching or exceeding predicted in vitro cytotoxic concentrations. Clinical adverse side effects including ptyalism and tachypnea exhibited during and post-IV infusion of IB-DNQ were transient and tolerable. Additionally, IB-DNQ administration did not produce acute or delayed-onset unacceptable hematologic, non-hematologic, or off-target oxidative toxicities. Collectively, the findings reported here within provide important safety and pharmacokinetic data to support the continued development of IB-DNQ as a novel anticancer strategy for NQO1 expressing cancers.",
keywords = "Comparative oncology, Deoxynyboquinone, Feline oral squamous cell carcinoma, NQO1, Novel anti-cancer agent, β-lapachone",
author = "Lundberg, {Alycen Paige} and Francis, {Joshua M.} and Malgorzata Pajak and Parkinson, {Elizabeth I.} and Wycislo, {Kathryn L.} and Rosol, {Thomas J.} and Brown, {Megan E.} and London, {Cheryl A.} and Levent Dirikolu and Paul Hergenrother and Fan, {Timothy M}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s10637-016-0414-z",
language = "English (US)",
volume = "35",
pages = "134--144",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species

AU - Lundberg, Alycen Paige

AU - Francis, Joshua M.

AU - Pajak, Malgorzata

AU - Parkinson, Elizabeth I.

AU - Wycislo, Kathryn L.

AU - Rosol, Thomas J.

AU - Brown, Megan E.

AU - London, Cheryl A.

AU - Dirikolu, Levent

AU - Hergenrother, Paul

AU - Fan, Timothy M

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1), an enzyme overexpressed in many solid tumors. Following activation by NQO1, IB-DNQ participates in a catalytic futile reduction/reoxidation cycle with consequent toxic reactive oxygen species generation within the tumor microenvironment. To elucidate the potential of IB-DNQ to serve as a novel anticancer agent, in vitro studies coupled with in vivo pharmacokinetic and toxicologic investigations in the domestic felid species were conducted to investigate the tractability of IB-DNQ as a translationally applicable anticancer agent. First, using feline oral squamous cell carcinoma (OSCC) as a comparative cancer model, expressions of NQO1 were characterized in not only human, but also feline OSCC tissue microarrays. Second, IB-DNQ mediated cytotoxicity in three immortalized feline OSCC cell lines were studied under dose-dependent and sequential exposure conditions. Third, the feasibility of administering IB-DNQ at doses predicted to achieve cytotoxic plasma concentrations and biologically relevant durations of exposure were investigated through pharmacokinetic and tolerability studies in healthy research felines. Intravenous administration of IB-DNQ at 1.0–2.0 mg/kg achieved peak plasma concentrations and durations of exposure reaching or exceeding predicted in vitro cytotoxic concentrations. Clinical adverse side effects including ptyalism and tachypnea exhibited during and post-IV infusion of IB-DNQ were transient and tolerable. Additionally, IB-DNQ administration did not produce acute or delayed-onset unacceptable hematologic, non-hematologic, or off-target oxidative toxicities. Collectively, the findings reported here within provide important safety and pharmacokinetic data to support the continued development of IB-DNQ as a novel anticancer strategy for NQO1 expressing cancers.

AB - Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1), an enzyme overexpressed in many solid tumors. Following activation by NQO1, IB-DNQ participates in a catalytic futile reduction/reoxidation cycle with consequent toxic reactive oxygen species generation within the tumor microenvironment. To elucidate the potential of IB-DNQ to serve as a novel anticancer agent, in vitro studies coupled with in vivo pharmacokinetic and toxicologic investigations in the domestic felid species were conducted to investigate the tractability of IB-DNQ as a translationally applicable anticancer agent. First, using feline oral squamous cell carcinoma (OSCC) as a comparative cancer model, expressions of NQO1 were characterized in not only human, but also feline OSCC tissue microarrays. Second, IB-DNQ mediated cytotoxicity in three immortalized feline OSCC cell lines were studied under dose-dependent and sequential exposure conditions. Third, the feasibility of administering IB-DNQ at doses predicted to achieve cytotoxic plasma concentrations and biologically relevant durations of exposure were investigated through pharmacokinetic and tolerability studies in healthy research felines. Intravenous administration of IB-DNQ at 1.0–2.0 mg/kg achieved peak plasma concentrations and durations of exposure reaching or exceeding predicted in vitro cytotoxic concentrations. Clinical adverse side effects including ptyalism and tachypnea exhibited during and post-IV infusion of IB-DNQ were transient and tolerable. Additionally, IB-DNQ administration did not produce acute or delayed-onset unacceptable hematologic, non-hematologic, or off-target oxidative toxicities. Collectively, the findings reported here within provide important safety and pharmacokinetic data to support the continued development of IB-DNQ as a novel anticancer strategy for NQO1 expressing cancers.

KW - Comparative oncology

KW - Deoxynyboquinone

KW - Feline oral squamous cell carcinoma

KW - NQO1

KW - Novel anti-cancer agent

KW - β-lapachone

UR - http://www.scopus.com/inward/record.url?scp=85006166035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006166035&partnerID=8YFLogxK

U2 - 10.1007/s10637-016-0414-z

DO - 10.1007/s10637-016-0414-z

M3 - Article

C2 - 27975234

AN - SCOPUS:85006166035

VL - 35

SP - 134

EP - 144

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -